Peregrine Pharmaceuticals to Report Third Quarter Fiscal 2015 Financial Results After Market on March 12, 2015
March 05 2015 - 04:00PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a
biopharmaceutical company focused on advancing bavituximab, a novel
immuno-oncology agent in Phase III development, today announced
that it will report financial results for the third quarter fiscal
year (FY) 2015 ended January 31, 2015 on March 12, 2015 after
market and will host a conference call and webcast at 1:30 PM
Pacific Daylight Time (4:30 PM Eastern Daylight Time). Peregrine's
senior management will discuss financial results for the third
quarter ended January 31, 2015 of FY 2015 and will review recent
progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast,
please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or
(253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company
with a pipeline of novel drug candidates in clinical trials for the
treatment and diagnosis of cancer. The company's lead
immuno-oncology candidate, bavituximab, is in Phase III development
for the treatment of second-line non-small lung cancer (the
"SUNRISE trial") along with several investigator-sponsored trials
evaluating other treatment combinations and additional oncology
indications. The company is also advancing a molecular imaging
agent, 124I-PGN650, in an exploratory clinical trial for the
imaging of multiple solid tumor types. Peregrine also has in-house
cGMP manufacturing capabilities through its wholly-owned subsidiary
Avid Bioservices, Inc. (www.avidbio.com), which provides
development and biomanufacturing services for both Peregrine and
third-party customers. Additional information about Peregrine can
be found at www.peregrineinc.com.
CONTACT: Christopher Keenan
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2023 to Mar 2024